Following a full submission
salmeterol/fluticasone 50/500 microgram inhaler (Seretide 500 Accuhaler) is not recommended for use within NHS Scotland for the symptomatic treatment of patients with chronic obstructive airways disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% to <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
While there was an improvement in lung function tests and a reduction in both moderate and severe exacerbations with salmeterol/fluticasone in comparison with placebo, there was no difference in mortality rate over 3 years. In addition, the manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Download detailed advice94KB (PDF)
Medicine details
- Medicine name:
- salmeterol fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler)
- SMC ID:
- 450/08
- Indication:
- For the symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 March 2008